Deucravacitinib (BMS-986165) is a chemical compound that has garnered interest in the pharmaceutical industry due to its potential as a treatment for various autoimmune diseases, such as psoriasis and psoriatic arthritis. This article will explore the chemical structure, health benefits, mechanisms of action, safety, and dosing of Deucravacitinib.
Chemical Name: Deucravacitinib has the chemical name 3-[(3R)-3-[3-(3-fluorophenyl)-1,2,4-triazol-5-yl]-4-methylpiperidin-1-yl]-3-oxopropanenitrile.
Molecular Formula: The molecular formula of Deucravacitinib is C20H22N8O3.
Formula Weight: The formula weight of Deucravacitinib is 422.45 g/mol.
CAS No: Deucravacitinib has a CAS No of 1609392-27-9.
Top Ten Keywords from Google and Synonyms:
- Deucravacitinib BMS-986165
- Autoimmune diseases treatment
- Psoriasis treatment
- Psoriatic arthritis
- Janus Kinase inhibitors
- JAK inhibitors
- Immunosuppressive agents
- Synthetic compound
- Rheumatoid arthritis
- BMS 986165
Health Benefits of Deucravacitinib: Deucravacitinib has shown potential as a treatment for psoriasis and psoriatic arthritis by reducing inflammation associated with these autoimmune diseases. It belongs to the class of Janus Kinase (JAK) inhibitors, which work by blocking the activity of certain enzymes that contribute to inflammation. By doing so, Deucravacitinib can reduce the severity and frequency of flare-ups associated with these autoimmune diseases.
Potential Effects of Deucravacitinib: Deucravacitinib has shown promising results in preclinical trials, demonstrating its potential as a treatment for autoimmune diseases like psoriasis, atopic dermatitis, and psoriatic arthritis. In a Phase II clinical trial, Deucravacitinib demonstrated a significant improvement in the Psoriasis Area and Severity Index (PASI) scores in patients with moderate to severe psoriasis. Furthermore, it has a more selective mechanism of action, which reduces the incidence of adverse effects associated with other JAK inhibitors.
Product Mechanism: Deucravacitinib works by inhibiting the activity of specific enzymes known as Janus Kinases (JAKs), which play a crucial role in inflammation pathways. By blocking these enzymes, Deucravacitinib stops the immune system from triggering inflammatory responses, ultimately alleviating the associated symptoms.
Safety: Deucravacitinib is still undergoing clinical trials, and its safety profile is in the early stages of being assessed. However, in clinical trials so far, Deucravacitinib has not demonstrated any significant safety issues.